200 related articles for article (PubMed ID: 23379600)
1. Real-time individual predictions of prostate cancer recurrence using joint models.
Taylor JM; Park Y; Ankerst DP; Proust-Lima C; Williams S; Kestin L; Bae K; Pickles T; Sandler H
Biometrics; 2013 Mar; 69(1):206-13. PubMed ID: 23379600
[TBL] [Abstract][Full Text] [Related]
2. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.
Pauler DK; Finkelstein DM
Stat Med; 2002 Dec; 21(24):3897-911. PubMed ID: 12483774
[TBL] [Abstract][Full Text] [Related]
3. Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer.
Desmée S; Mentré F; Veyrat-Follet C; Sébastien B; Guedj J
BMC Med Res Methodol; 2017 Jul; 17(1):105. PubMed ID: 28716060
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach.
Proust-Lima C; Taylor JM
Biostatistics; 2009 Jul; 10(3):535-49. PubMed ID: 19369642
[TBL] [Abstract][Full Text] [Related]
5. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Sun LL; Moul JW; Freedland SJ
Int J Urol; 2010 Nov; 17(11):914-22. PubMed ID: 20880361
[TBL] [Abstract][Full Text] [Related]
6. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782
[TBL] [Abstract][Full Text] [Related]
7. A two-stage model in a Bayesian framework to estimate a survival endpoint in the presence of confounding by indication.
Bellera C; Proust-Lima C; Joseph L; Richaud P; Taylor J; Sandler H; Hanley J; Mathoulin-Pélissier S
Stat Methods Med Res; 2018 Apr; 27(4):1271-1281. PubMed ID: 27587597
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995.
Preston DM; Bauer JJ; Connelly RR; Sawyer T; Halligan J; Leifer ES; McLeod DG; Moul JW
Urology; 1999 Jan; 53(1):131-8. PubMed ID: 9886602
[TBL] [Abstract][Full Text] [Related]
9. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
10. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
[TBL] [Abstract][Full Text] [Related]
11. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
12. Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM.
Riglet F; Mentre F; Veyrat-Follet C; Bertrand J
AAPS J; 2020 Feb; 22(2):50. PubMed ID: 32076894
[TBL] [Abstract][Full Text] [Related]
13. Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence.
Gretzer MB; Epstein JI; Pound CR; Walsh PC; Partin AW
Urology; 2002 Dec; 60(6):1034-9. PubMed ID: 12475665
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.
Laajala TD; Seikkula H; Seyednasrollah F; Mirtti T; Boström PJ; Elo LL
Sci Rep; 2016 Nov; 6():36161. PubMed ID: 27805011
[TBL] [Abstract][Full Text] [Related]
16. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.
Grossfeld GD; Latini DM; Lubeck DP; Broering JM; Li YP; Mehta SS; Carroll PR
Urology; 2002 Apr; 59(4):560-5. PubMed ID: 11927314
[TBL] [Abstract][Full Text] [Related]
17. Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue volume in patients undergoing radical prostatectomy: a new predictor of biochemical recurrence in localized or locally advanced prostate cancer.
Ku JH; Moon KC; Cho SY; Kwak C; Kim HH
Asian J Androl; 2011 Mar; 13(2):248-53. PubMed ID: 21102474
[TBL] [Abstract][Full Text] [Related]
18. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations.
Lee WR; Hanks GE; Hanlon A
J Clin Oncol; 1997 Jan; 15(1):230-8. PubMed ID: 8996147
[TBL] [Abstract][Full Text] [Related]
19. Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer.
Okegawa T; Noda H; Kato M; Miyata A; Nutahara K; Higashihara E
Prostate; 2000 Aug; 44(3):210-8. PubMed ID: 10906737
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
